This document discusses Microbial Robotics' open synthetic biology model and business plan. The company aims to rapidly prototype synthetic biology-based bacteria and viruses for industry experts through an open model. By shipping consumables, platforms, and knowledge across borders instead of genetically modified organisms, the company solves issues around international shipping restrictions. The company also focuses on achieving rapid return on investment through its Open Therapeutics subsidiary and exit strategy within 5 years of starting projects. Projections estimate strong revenue, margin, and EBITDA growth through 2019 as subsidiaries are acquired by larger companies.
Biosimilars: Regulatory and Clinical ConsiderationsCovance
Other considerations for clinical studies are that the regulations are written with some flexibility, and although clinical studies have been required thus far, they are not mandated by the regulations. Perception from sponsors is that innovators make process changes all the time that impact structure and no clinical study is done because of good analytical characterization so why are biosimilars different? With solid analytical and functional data, we should continue to challenge regulators on the need for clinical studies.
DIA 2014 Marketing Pharmaceuticals Conf Marketing in Age of ObamaDale Cooke
This is my portion of the session I led at the DIA 2014 Marketing Pharmaceuticals Conference about the impact of some of the recent legislative changes on people responsible for marketing pharmaceuticals in the United States.
If your medical device has contact with human tissue, it is a safe bet that you will be required to conduct biocompatibility testing. Biocompatibility testing is used to determine the “potential for an unacceptable adverse biological response resulting from contact of the component materials of the device with the body”. The FDA relies heavily on ISO 10993 as the guiding force for biocompatibility testing in medical devices. This ISO standard is rooted in a risk-based approach to testing that the FDA views as the gold standard to ensure that medical devices do not cause adverse local or systemic effects due to contact with human tissue...
Biosimilars: Regulatory and Clinical ConsiderationsCovance
Other considerations for clinical studies are that the regulations are written with some flexibility, and although clinical studies have been required thus far, they are not mandated by the regulations. Perception from sponsors is that innovators make process changes all the time that impact structure and no clinical study is done because of good analytical characterization so why are biosimilars different? With solid analytical and functional data, we should continue to challenge regulators on the need for clinical studies.
DIA 2014 Marketing Pharmaceuticals Conf Marketing in Age of ObamaDale Cooke
This is my portion of the session I led at the DIA 2014 Marketing Pharmaceuticals Conference about the impact of some of the recent legislative changes on people responsible for marketing pharmaceuticals in the United States.
If your medical device has contact with human tissue, it is a safe bet that you will be required to conduct biocompatibility testing. Biocompatibility testing is used to determine the “potential for an unacceptable adverse biological response resulting from contact of the component materials of the device with the body”. The FDA relies heavily on ISO 10993 as the guiding force for biocompatibility testing in medical devices. This ISO standard is rooted in a risk-based approach to testing that the FDA views as the gold standard to ensure that medical devices do not cause adverse local or systemic effects due to contact with human tissue...
Maximize your Share of the Multi-Billion Dollar Biosimilars MarketDyan Cornacchio
Experts are estimating the global biosimilars market to be worth more than $11 billion by 2021- now is the time to learn best practices and strategies to maximize your position in this robust market.
Whether you are on the innovator or biosimilar side, ACI’s 8th Annual Summit on Biosimilars (https://goo.gl/4mtUUF) will help you develop and protect your biologics portfolio as our stellar faculty of experts discuss these featured topics:
• Policy and Politics of Biosimilars under the New Administration
• Untangling the Inner Workings of IPRs for Biosimilars
• Shall we Dance: Mastering the “Steps” of the BPCIA while Avoiding Common Pitfalls
View Agenda - https://goo.gl/454z9D
Don’t miss your chance to grab a piece of this exponentially growing market and register today! Mention Registration Code: B00-658-LNK17 when registering!
Anthony Presentation DIA Florida Ctd Nov2007AKTaylor
Creating a business process that is accurate, predictable, and capable of
meeting the changing needs for disclosing information about clinical trials
in multiple study registries and results databases is difficult. Companies
need to leverage their current clinical trial process, determine if the disclosure
steps will be centralized or decentralized, determine how much to
leverage technology, and decide whether, and how, to use outside
resources. During this session, we will hear how a large pharma, a small
biopharmaceutical company, and a device company developed their clinical
trial disclosure business process.
5th Biosimilars Congregation 2014
10th September 2014, Kohinoor Continental Hotel, Mumbai, India
“Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars”
Building Your Employer Brand with Social MediaLuanWise
Presented at The Global HR Summit, 6th June 2024
In this keynote, Luan Wise will provide invaluable insights to elevate your employer brand on social media platforms including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok. You'll learn how compelling content can authentically showcase your company culture, values, and employee experiences to support your talent acquisition and retention objectives. Additionally, you'll understand the power of employee advocacy to amplify reach and engagement – helping to position your organization as an employer of choice in today's competitive talent landscape.
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
Maximize your Share of the Multi-Billion Dollar Biosimilars MarketDyan Cornacchio
Experts are estimating the global biosimilars market to be worth more than $11 billion by 2021- now is the time to learn best practices and strategies to maximize your position in this robust market.
Whether you are on the innovator or biosimilar side, ACI’s 8th Annual Summit on Biosimilars (https://goo.gl/4mtUUF) will help you develop and protect your biologics portfolio as our stellar faculty of experts discuss these featured topics:
• Policy and Politics of Biosimilars under the New Administration
• Untangling the Inner Workings of IPRs for Biosimilars
• Shall we Dance: Mastering the “Steps” of the BPCIA while Avoiding Common Pitfalls
View Agenda - https://goo.gl/454z9D
Don’t miss your chance to grab a piece of this exponentially growing market and register today! Mention Registration Code: B00-658-LNK17 when registering!
Anthony Presentation DIA Florida Ctd Nov2007AKTaylor
Creating a business process that is accurate, predictable, and capable of
meeting the changing needs for disclosing information about clinical trials
in multiple study registries and results databases is difficult. Companies
need to leverage their current clinical trial process, determine if the disclosure
steps will be centralized or decentralized, determine how much to
leverage technology, and decide whether, and how, to use outside
resources. During this session, we will hear how a large pharma, a small
biopharmaceutical company, and a device company developed their clinical
trial disclosure business process.
5th Biosimilars Congregation 2014
10th September 2014, Kohinoor Continental Hotel, Mumbai, India
“Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars”
Building Your Employer Brand with Social MediaLuanWise
Presented at The Global HR Summit, 6th June 2024
In this keynote, Luan Wise will provide invaluable insights to elevate your employer brand on social media platforms including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok. You'll learn how compelling content can authentically showcase your company culture, values, and employee experiences to support your talent acquisition and retention objectives. Additionally, you'll understand the power of employee advocacy to amplify reach and engagement – helping to position your organization as an employer of choice in today's competitive talent landscape.
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
Understanding User Needs and Satisfying ThemAggregage
https://www.productmanagementtoday.com/frs/26903918/understanding-user-needs-and-satisfying-them
We know we want to create products which our customers find to be valuable. Whether we label it as customer-centric or product-led depends on how long we've been doing product management. There are three challenges we face when doing this. The obvious challenge is figuring out what our users need; the non-obvious challenges are in creating a shared understanding of those needs and in sensing if what we're doing is meeting those needs.
In this webinar, we won't focus on the research methods for discovering user-needs. We will focus on synthesis of the needs we discover, communication and alignment tools, and how we operationalize addressing those needs.
Industry expert Scott Sehlhorst will:
• Introduce a taxonomy for user goals with real world examples
• Present the Onion Diagram, a tool for contextualizing task-level goals
• Illustrate how customer journey maps capture activity-level and task-level goals
• Demonstrate the best approach to selection and prioritization of user-goals to address
• Highlight the crucial benchmarks, observable changes, in ensuring fulfillment of customer needs
Recruiting in the Digital Age: A Social Media MasterclassLuanWise
In this masterclass, presented at the Global HR Summit on 5th June 2024, Luan Wise explored the essential features of social media platforms that support talent acquisition, including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok.
B2B payments are rapidly changing. Find out the 5 key questions you need to be asking yourself to be sure you are mastering B2B payments today. Learn more at www.BlueSnap.com.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
FIA officials brutally tortured innocent and snatched 200 Bitcoins of worth 4...jamalseoexpert1978
Farman Ayaz Khattak and Ehtesham Matloob are government officials in CTW Counter terrorism wing Islamabad, in Federal Investigation Agency FIA Headquarters. CTW and FIA kidnapped crypto currency owner from Islamabad and snatched 200 Bitcoins those worth of 4 billion rupees in Pakistan currency. There is not Cryptocurrency Regulations in Pakistan & CTW is official dacoit and stealing digital assets from the innocent crypto holders and making fake cases of terrorism to keep them silent.
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
Exploring Patterns of Connection with Social Dreaming
Microbial Robotics briefing
1. THIS
IS
NOT
AN
OFFERING
TO
BUY
OR
SELL
SECURITIES
Safe
Harbor
for
Forward-‐Looking
Statements
Except for the statements of historical fact, the information presented herein constitutes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of
Microbial Robotics LLC (the “Company”) to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Such factors include general economic and business conditions,
the ability to fund operations, the ability to forge partnerships required for deployment, changes in consumer and corporate
buying habits, energy development, production, and distribution, the rapid pace of change in the technology industry and
other factors over which the Companies have little or no control. The Companies assume no obligation to publicly update or
revise any forward-looking statements. A full Risk Disclosure is available within the business plan.
Your advancement beyond this page or slide into this document indicates you read and understand this disclosure. The
remaining aspects of this document are confidential. The contents should not be disclosed beyond you without the
expressed written consent of the Company.
1
2. WITH SMALL
ORGANISMS
With an Open model, rapidly prototyping synthetic biology-based bacteria
and viruses for chemical, therapeutic, and water industry experts.
SOLVING BIG PROBLEMS
JASON E. BARKELOO, CEO
3. WHY OPEN SYNTHETIC BIOLOGY MODEL?
[11] United States Patent and Trademark Office, Patent Pools:A Solution to the Problem of Access in Biotechnology Patents? (Dec 5, 2000)
available at http://www.uspto.gov/web/offices/pac/dapp/opla/patentpool.pdf .The USPTO noted two of the most profitable in the biotechnology
area are those of Cohen and Boyer, which are owned by Stanford University. Stanford minimized licensing fees and extended non-exclusive
licenses.This discouraged would-be infringers since the cost of obtaining a license is low. Instead of encourage infringement and patent trolling,
the ease of non-exclusive licenses meant broad distribution and spurred further innovation. See also National Research Council, Intellectual
Property Rights and Research Tools in Molecular Biology (1996), available at http://www.nap.edu/readingroom/books/property/5.html.
“With respect to biologics commercialization, the U.S. Patent andTrademark Office
(USPTO) specifically noted the open (patent-pool) approach:
‘No single company or organization, however, has the resources to develop any
significant fraction of the genetic information present in an organism. If proprietary
information is not freely available or licensed in an affordable manner, researchers
will be precluded from using these protected nucleic acids to develop new
therapeutics and diagnostics. It would be, however, shortsighted of a patent holder
to demand such a prohibitively expensive licensing agreement that would preclude
anyone else from utilizing a patented invention. . . . By minimizing licensing fees and
extending non-exclusive licenses, potential infringers were inclined to obtain
licenses and the technology was therefore broadly distributed. . . .’[11]”
5. YEARS
Pablo Pomposiello
PhD
Bacterial Physiology
Consultant
Timothy P. Cripe
MD, PhD
Oncolytics Consultant
Ravi N. Samy
MD, FACS
Chief Medical Officer
Jason E. Barkeloo
MA
Founder & CEO
Shengchang Su
PhD
Director
MicrobialBots and
GeRM Engineering
Li Guo
PhD
Director
Cellular
Engineering
Jay Springer
JD
Director
Regulatory
and Legal Affairs
Jin Kong
JD
Director
GlobalSynBio &
Open Therapeutics
EXPERIENCE
100+
K. Krishnamoorthy
MD
Chief Medical Officer
India
6. “Imagine a cancer cure
without the destructive side effects of chemotherapy.
This leader in pediatric research is doing just that.”